These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9108966)

  • 1. Zidovudine-resistant variants of HIV-1 in lung.
    Gates A; Coker R; Miller R; Mitchell D; Williamson J; Clarke J
    AIDS; 1997 Apr; 11(5):702-3. PubMed ID: 9108966
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiretroviral treatment and resistance].
    Gómez-Cano M; Villalba N; Mas A; Holguín A; Soriano V
    Rev Clin Esp; 1997 Aug; 197(8):574-82. PubMed ID: 9312796
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview on HIV-1-related drug resistance: from theory to clinical practice.
    Moroni M; Balotta C; Rusconi S
    J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):15-8. PubMed ID: 9689573
    [No Abstract]   [Full Text] [Related]  

  • 4. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
    Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC
    J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.
    Parkin NT; Lie YS; Hellmann N; Markowitz M; Bonhoeffer S; Ho DD; Petropoulos CJ
    J Infect Dis; 1999 Sep; 180(3):865-70. PubMed ID: 10438382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
    Batisse D; Karmochkine M; Si Mohamed A; Piketty C; Kazatchkine MD; Belec L
    AIDS; 1998 May; 12(7):824-5. PubMed ID: 9619820
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors.
    Quigg M; Rebus S; France AJ; McMenamin J; Darby G; Leigh Brown AJ
    AIDS; 1997 May; 11(6):835-6. PubMed ID: 9143628
    [No Abstract]   [Full Text] [Related]  

  • 10. Decline of HIV-1 RNA in cerebrospinal fluid during zidovudine treatment.
    Portegies P; Danner SA; Enting RH; Meilof J; de Wolf F; Goudsmit J
    Antivir Ther; 1996 Aug; 1(3):195. PubMed ID: 11322255
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
    Dykes C; Najjar J; Bosch RJ; Wantman M; Furtado M; Hart S; Hammer SM; Demeter LM
    J Infect Dis; 2004 Mar; 189(6):1091-6. PubMed ID: 14999613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular mechanisms for the emergence of drug-resistant HIV-1].
    Mitsuya H
    Tanpakushitsu Kakusan Koso; 2000 Sep; 45(12):1899-908. PubMed ID: 10998958
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV and multidrug resistance.
    Emini EA; Graham DJ; Gotlib L; Condra JH; Byrnes VW; Schleif WA
    Nature; 1993 Aug; 364(6439):679. PubMed ID: 7689173
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multiple benefits associated with HIV drug-resistance mutation M184V.
    Bean P
    Am Clin Lab; 2002 Mar; 21(2):16-8. PubMed ID: 11993249
    [No Abstract]   [Full Text] [Related]  

  • 17. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
    Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
    Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
    Bélec L; Legoff J; Si-Mohamed A; Andréoletti L; Mbopi-Kéou FX; Kolberg J; Matta M; Detmer J; Piketty C; Kazatchkine MD
    J Med Virol; 2002 Sep; 68(1):1-6. PubMed ID: 12210423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.